EGFR and small cell lung carcinoma: Interestingly, previous genomic profiling identified mutations in several WNT pathway members and increased WNT/β-catenin signaling in T-SCLC patient tumors, although in that work, combined treatment of a mixed LUAD/SCLC PDX with a WNT and EGFR inhibitor did not improve survival beyond an EGFR inhibitor alone [55], suggesting that WNT signaling was not critical in that context.